Objective: To assess the clinical effectiveness of postauricular injection of methylprednisolone in the treatment of individuals with sudden deafness (SD) and to identify influencing factors.
Methodology: In this retrospective study, we included clinical data of 106 eligible patients with SD who were hospitalized in the Department of Otorhinolaryngology of Nanjing Integrated Traditional Chinese and Western Medicine Hospital from October 2023 to October 2024. According to the different routes of administration of methylprednisolone, patients were divided into an observation (OBP) (n=54) and a control (CGP) (n=52) group. The CGP group received routine treatment of intravenous methylprednisolone combined with conventional medication and the OBP group received retroauricular injection of methylprednisolone in addition to the routine treatment.
Results: Patients in the OBP group reported a considerably better overall efficacy (87.0% vs. 67.3%) and tinnitus (74.1% vs. 60.7%) than the CGP group. The vertigo disappearance time (5.19±1.29 d vs 5.35±1.06 d) and ear fullness sensation halo disappearance time (5.73±1.21 d vs 6.16±1.27 d) in the OBP group were considerably shorter than in the CGP group (P<0.05). Levels of Homocysteine (HCY), High Shear Blood Viscosity (HBV), Low Shear Blood Viscosity (LBV), Plasma Viscosity (PV) and Hematocrit (HCT) in both groups decreased significantly after therapy and were substantially lower in the OBP group compared to the CGP group (p < 0.05).
Conclusion: Compared to conventional treatment, postauricular injection of methylprednisolone can enhance the treatment efficacy of SD and is associated with improvement in accompanying symptoms. Postauricular injection of methylprednisolone can more effectively reduce HCY, HBV, LBV, PV and HCT levels in SD patients.
扫码关注我们
求助内容:
应助结果提醒方式:
